Physician profile
Leili Behrooz
NPI 1750811386
$555.17
in general payments reported to CMS, 2019-2025
8 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $78.91 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $223.75 | 2025 | Repatha |
| Biotronik INC. | $128.81 | 2025 | |
| Abiomed | $79.06 | 2025 | |
| Heartflow, INC. | $35.67 | 2024 | |
| Abbott Laboratories | $22.49 | 2025 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $22.46 | 2024 | Camzyos |
| Cvrx, INC. | $22.15 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $20.78 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leili Behrooz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.